R-Alpha Lipoic Acid (R-ALA).

The reduced form of lipoic acid, dihydrolipoic acid, donates electrons back to oxidised glutathione and raises cysteine availability for glutathione synthesis. The two sit on the same cellular antioxidant recycling network rather than acting in parallel.

Dihydrolipoic acid reduces dehydroascorbate back to ascorbate, so lipoic acid extends how long a given pool of vitamin C keeps working. Ascorbate in turn recycles the tocopheryl radical, linking the water and lipid compartments.

Lipoic acid feeds the ascorbate step that regenerates alpha-tocopherol from its radical form after it quenches a lipid peroxyl radical. Lipoic acid is both water and fat soluble, so it bridges to the membrane pool that vitamin E defends.

Dihydrolipoic acid can reduce ubiquinone to ubiquinol, restoring the active form that carries electrons in the respiratory chain. Both sit inside the mitochondrion, so the recycling happens where the demand is.

Acetyl-L-carnitine moves acetyl and fatty acyl groups across the mitochondrial membrane for oxidation, while the lipoamide arm of pyruvate dehydrogenase transfers acetyl units onto coenzyme A for the citric acid cycle. The two sit on adjacent steps of the same fuel handling sequence.

Pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase need thiamine pyrophosphate and lipoamide on the same complex, in sequence. Neither cofactor completes the decarboxylation step without the other present.

Benfotiamine raises tissue thiamine pyrophosphate, the cofactor that sits immediately upstream of the lipoamide arm on the same dehydrogenase complexes lipoic acid serves. Formulators pair them for that shared step in normal glucose oxidation.

Lipoic acid and biotin both enter cells through the sodium-dependent multivitamin transporter, so a high lipoic acid intake competes with biotin uptake. Formulations that carry generous lipoic acid usually add biotin for that reason.

Lipoic acid and its reduced form chelate divalent and trivalent metal ions, including iron, which can lower the fraction of an iron dose that stays available for uptake. Separating the two by a few hours is the usual formulation answer.

Dihydrolipoamide dehydrogenase uses NAD as the electron acceptor that returns lipoamide to its oxidised, working form. Without adequate NAD the lipoyl arm stays reduced and the complex stalls.

NAC supplies the cysteine that limits how much glutathione a cell can build, while lipoic acid keeps the glutathione already present in its reduced form. One adds to the pool, the other maintains it.

Both act on normal insulin signalling and glucose uptake by muscle, through different steps, so their effects on blood sugar can add up. Anyone already using something that lowers blood sugar should account for that overlap.

Thioredoxin reductase, a selenoenzyme, is one of the routes that reduces lipoic acid to its active dithiol form. Adequate selenium status therefore supports the recycling capacity lipoic acid depends on.

Lipoic acid works inside the pyruvate and alpha-ketoglutarate dehydrogenase complexes as a covalently bound lipoamide arm. After each catalytic cycle the E3 subunit, an FAD-containing enzyme built on riboflavin, has to reoxidise it. Without adequate riboflavin the lipoamide arm stays reduced and the complex stalls. Textbook enzymology, no trial needed.

Electrons pass from reduced lipoamide to FAD and then to NAD+, so the whole cycle depends on an available NAD+ pool. Niacin is the precursor of that pool. This places lipoic acid, riboflavin and niacin in one continuous electron chain.

Coenzyme A, derived from pantothenic acid, accepts the acetyl group that the lipoamide arm hands off inside the pyruvate dehydrogenase complex, so the two are consecutive in one reaction. Separately, lipoic acid, biotin and pantothenate all use the sodium-dependent multivitamin transporter to cross the intestinal wall, which makes their uptake mutually competitive at high doses. The pairing therefore runs in both directions and both are worth saying.

Thiamine pyrophosphate binds its enzyme through a magnesium ion, and the E1 decarboxylation step is what delivers the acyl group to the lipoamide arm. A magnesium shortfall constrains the step immediately before lipoic acid's role. Established coordination chemistry rather than a combination finding.

Dihydrolipoic acid is a dithiol and binds copper and other transition metals, which is one of the described antioxidant mechanisms of the molecule. The same chemistry means a large lipoic acid dose taken at the same time as a mineral can reduce that mineral's availability. Separating them in the day is the ordinary formulation answer.

The reduced dithiol form of lipoic acid coordinates divalent metal ions, zinc included. Taken together in one dose that binding can reduce how much of the mineral is absorbed. This is a timing consideration, stated as direction and not as a warning.

Manganese is a divalent transition metal of the class that dihydrolipoic acid binds. The interaction is inferred from the general metal-binding behaviour of the dithiol rather than from a manganese-specific study, so the confidence stays mid. Direction is the useful part of the row.

Dihydrolipoic acid reduces oxidised glutathione back to its active form, and cysteine availability sets how much glutathione there is to recycle. The two act at different points of one thiol economy. Straight biochemistry, no combination trial implied.

Glycine is the third residue of the glutathione tripeptide and can limit the final synthesis step. A bigger reduced glutathione pool gives dihydrolipoic acid more substrate to act on. Complementary positions in the same pathway.

Glutamine is deamidated to glutamate, the first residue of glutathione. In tissues with high glutathione turnover glutamine supply becomes part of what sets the pool size. Lipoic acid then acts on that pool by keeping it reduced.

Alpha lipoic acid has been formulated together with a B-complex including B12 and studied for effects on nerve conduction and symptom measures. B12 is separately required for methylmalonyl-CoA mutase and for methionine synthase, both relevant to nerve tissue maintenance. The pairing is a published formulation combination rather than an isolated mechanistic claim.

A published protocol paired alpha lipoic acid with resveratrol, acetyl-L-carnitine and cholecalciferol alongside rehabilitation. Resveratrol and lipoic acid both act on redox-sensitive signalling, so the rationale for the pair is a shared regulatory pathway. Because the intervention had four components, no effect can be attributed to any one of them.

Cholecalciferol appeared alongside alpha lipoic acid in a published combined rehabilitation protocol. The two have separate mechanisms, so this is a formulation co-occurrence rather than a mechanistic partnership. The multi-component design means the contribution of each is not separable.

A 2026 review groups alpha-lipoic acid, urolithin A and ergothioneine as nutritional agents acting on mitochondrial redox handling. Urolithin A is a gut microbial metabolite of ellagitannins with a described role in mitochondrial turnover, while lipoic acid sits inside the dehydrogenase complexes. The overlap is conceptual and review-level, not a combination trial.

Ergothioneine is a thione taken into cells by a dedicated transporter and behaves as a thiol-class antioxidant, the same broad chemistry as the dithiolane ring of lipoic acid. A review groups the two as complementary redox agents. Review-level grouping, so the confidence stays mid.

A poultry study combined encapsulated probiotics with alpha-lipoic acid and reported changes in blood parameters and gut measures. This is an animal production study, so it is not evidence of an effect in people. It is recorded here as a documented co-administration, labelled as such.

Ubiquinol carries electrons within the inner mitochondrial membrane while lipoamide carries them inside the dehydrogenase complexes that feed it, so the two sit consecutively in the same energy pathway. A published analytical method quantifies ubiquinol, ubiquinone and alpha-lipoic acid together in serum, which reflects how closely the redox couples are read as one picture. The pairing rests on shared pathway position rather than on a combination outcome trial.

Only the R enantiomer is the form made by the body and bound as lipoamide in the dehydrogenase complexes. The S enantiomer is a synthesis artefact of the racemic route and behaves differently in transport and metabolism. Taking both is not additive in the ordinary sense, since half the racemic dose is the other stereoisomer.

B6 in its P5P form is the cofactor of transaminases and of several steps in amino acid and neurotransmitter handling. It appears in the B-complex preparations that have been paired with alpha lipoic acid in published work. The link is formulation practice supported by separate established cofactor roles.